A listed company developing circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has appointed an interim CEO.

ANGLE plc recently announced that chief exec Andrew Newland and finance chief Ian Griffiths would be ‘transitioned’ out of the business but have their contractual entitlements honoured over the next 12 months.

Chairman Dr Jan Groen moved into an executive role to lead the company as it pursues a revised strategy, focused on tight cost control, accelerated commercial progress and a clear plan towards becoming a sustainable business.

Now this morning it has appointed Peter Collins as interim CEO, while Klaas de Boer joins as a senior advisor to the board.

Collins has held senior executive positions across both private and publicly listed companies. He joins following a series of successful leadership roles at leading oncology diagnostics organisations, including SAGA Diagnostics, Inivata, Guardant Health and GSK.

The company has a cash runway into Q1 2026 and will need to raise funds in the coming months.